FR21C1055I2 - Composition comprenant un anticorps anti-interleukine 13 - Google Patents

Composition comprenant un anticorps anti-interleukine 13

Info

Publication number
FR21C1055I2
FR21C1055I2 FR21C1055C FR21C1055C FR21C1055I2 FR 21C1055 I2 FR21C1055 I2 FR 21C1055I2 FR 21C1055 C FR21C1055 C FR 21C1055C FR 21C1055 C FR21C1055 C FR 21C1055C FR 21C1055 I2 FR21C1055 I2 FR 21C1055I2
Authority
FR
France
Prior art keywords
interleukin
antibody
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1055C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37434894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1055(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0519923.7A external-priority patent/GB0519923D0/en
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of FR21C1055I1 publication Critical patent/FR21C1055I1/fr
Application granted granted Critical
Publication of FR21C1055I2 publication Critical patent/FR21C1055I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
FR21C1055C 2005-09-30 2021-11-16 Composition comprenant un anticorps anti-interleukine 13 Active FR21C1055I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72197405P 2005-09-30 2005-09-30
GBGB0519923.7A GB0519923D0 (en) 2005-09-30 2005-09-30 Interleukin-13 antibody composition
PCT/GB2006/003650 WO2007036745A2 (fr) 2005-09-30 2006-09-29 Composition comprenant un anticorps anti-interleukine 13

Publications (2)

Publication Number Publication Date
FR21C1055I1 FR21C1055I1 (fr) 2021-12-24
FR21C1055I2 true FR21C1055I2 (fr) 2022-11-18

Family

ID=37434894

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1055C Active FR21C1055I2 (fr) 2005-09-30 2021-11-16 Composition comprenant un anticorps anti-interleukine 13

Country Status (20)

Country Link
US (3) US20080248048A1 (fr)
EP (1) EP1942939B2 (fr)
JP (2) JP2009510046A (fr)
KR (1) KR101363777B1 (fr)
AU (1) AU2006296399B2 (fr)
BR (1) BRPI0616359B8 (fr)
CA (1) CA2623429C (fr)
CY (1) CY1120874T1 (fr)
FI (1) FIC20210042I1 (fr)
FR (1) FR21C1055I2 (fr)
GB (1) GB2430883B (fr)
HK (1) HK1210724A1 (fr)
HU (1) HUS2100053I1 (fr)
IL (3) IL189983A (fr)
LT (1) LTPA2021528I1 (fr)
NL (1) NL301143I2 (fr)
NO (2) NO344859B1 (fr)
PL (1) PL1942939T5 (fr)
SI (1) SI1942939T2 (fr)
WO (1) WO2007036745A2 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420086B2 (en) * 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
LT2805728T (lt) 2003-12-23 2020-05-25 Genentech, Inc. Nauji anti-il 13 antikūnai ir jų naudojimai
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
EP3088410A3 (fr) 2006-04-05 2016-12-28 AbbVie Biotechnology Ltd Purification d'anticorps
WO2008086395A2 (fr) * 2007-01-09 2008-07-17 Wyeth Préparations d'anticorps ant-il-13 et leurs utilisations
JP5513380B2 (ja) * 2007-06-25 2014-06-04 アムジエン・インコーポレーテツド 肝細胞増殖因子に対する特異的結合剤の組成物
WO2009009406A1 (fr) * 2007-07-06 2009-01-15 Smithkline Beecham Corporation Formulations d'anticorps
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
SG2014014138A (en) 2008-03-31 2014-07-30 Genentech Inc Compositions and methods for treating and diagnosing asthma
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
CN104744560A (zh) 2009-10-20 2015-07-01 Abbvie公司 使用蛋白a亲和色谱法分离和纯化抗-il-13抗体
NZ609493A (en) 2010-12-16 2015-11-27 Genentech Inc Diagnosis and treatments relating to th2 inhibition
AR085911A1 (es) 2011-03-16 2013-11-06 Sanofi Sa Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
EP2694708A4 (fr) * 2011-04-07 2014-10-01 Glaxosmithkline Llc Formulations à viscosité réduite
AU2012283039A1 (en) 2011-07-13 2014-01-30 Abbvie Inc. Methods and compositions for treating asthma using anti-IL-13 antibodies
CN109078182B (zh) 2011-10-31 2022-08-12 弗·哈夫曼-拉罗切有限公司 抗体制剂
WO2013148232A1 (fr) 2012-03-27 2013-10-03 Genentech, Inc. Procédés applicables au pronostic, au diagnostic, et au traitement de la fibrose pulmonaire idiopathique
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
SG11201601823TA (en) * 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
MX2016005159A (es) 2013-10-23 2016-07-05 Genentech Inc Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
JP2014062100A (ja) * 2013-11-05 2014-04-10 Glaxosmithkline Llc 抗体処方
EP3107574A2 (fr) 2014-02-21 2016-12-28 F. Hoffmann-La Roche AG Anticorps bispécifiques anti-il-13/il-17 et leurs utilisations
SG11201606702SA (en) * 2014-02-27 2016-09-29 Univ Texas Methods and compositions for isolating exosomes
MX2016013372A (es) 2014-04-11 2017-01-26 Novartis Ag Metodos de tratar selectivamente el asma utilizando antagonistas de il-13.
JP6247241B2 (ja) * 2015-02-27 2017-12-13 ノバルティス アーゲー 抗体処方
AU2016233398A1 (en) 2015-03-16 2017-09-07 F. Hoffmann-La Roche Ag Methods of detecting and quantifying IL-13 and uses in diagnosing and treating Th2-associated diseases
WO2017139290A1 (fr) * 2016-02-10 2017-08-17 Medimmune, Llc Dispositif d'administration de tralokinumab
UA124269C2 (uk) 2016-09-23 2021-08-18 Дженентек, Інк. Застосування антагоністу il-13 для лікування атопічного дерматиту
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7418337B2 (ja) 2018-02-09 2024-01-19 ジェネンテック， インコーポレイテッド マスト細胞媒介性炎症性疾患の治療法及び診断法
WO2020092015A1 (fr) 2018-11-02 2020-05-07 University Of Rochester Atténuation thérapeutique d'une infection épithéliale
JP2023534576A (ja) 2020-03-23 2023-08-10 メドイミューン・リミテッド アトピー性皮膚炎及び関連する障害の治療方法
GB202108379D0 (en) 2021-06-11 2021-07-28 Medlmmune Ltd Methods for treating a topic dermatitis and related disorders
TW202325731A (zh) 2021-08-16 2023-07-01 美商麥迪紐有限責任公司 抗ｉｌ—１３抗體調配物
AU2022345969A1 (en) 2021-09-15 2024-03-07 Dermira, Inc. Il-13 inhibitors for the treatment of prurigo nodularis
WO2023052408A1 (fr) 2021-09-28 2023-04-06 Medimmune Limited Méthodes de traitement de la dermatite atopique et de troubles apparentés

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685919B1 (fr) * 1992-01-08 1994-04-08 Elf Sanofi Proteine a activite de type cytokine, adn recombinant codant pour cette proteine, cellules animales transformees.
HU217099B (hu) 1991-03-29 1999-11-29 Elf Sanofi Sa. Eljárás citokin típusú aktivitással rendelkező fehérje, azt kódoló rekombináns DNS-szekvencia és a megfelelő transzformált sejtek és mikroorganizmusok előállítására
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
JPH07267994A (ja) * 1994-03-31 1995-10-17 Snow Brand Milk Prod Co Ltd 新規蛋白質及びその製造法
JP3414856B2 (ja) * 1994-08-09 2003-06-09 株式会社ヤトロン ジフェニルエーテル化合物の免疫学的測定方法
US5866154A (en) † 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
HUP9901562A3 (en) † 1996-05-04 2000-06-28 Astrazeneca Ab Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
WO1998056418A1 (fr) 1997-06-13 1998-12-17 Genentech, Inc. Formulation stabilisee renfermant un anticorps
ES2229784T3 (es) † 1998-06-09 2005-04-16 Statens Serum Institut Proceso de produccion de inmunoglobulinas para administracion intravenosa y otros productos de inmunoglobulina.
JP3537331B2 (ja) * 1998-11-17 2004-06-14 積水化学工業株式会社 Ｉｖ型コラーゲンの免疫測定法及び試薬
US7323311B2 (en) † 2000-03-03 2008-01-29 Cambridge Antibody Technology Limited Methods of obtaining a specific binding member that binds eotaxin
EP1175931A1 (fr) † 2000-07-25 2002-01-30 Computer Cell Culture Center S.A. Intégration de la mise en oeuvre d'un bioréacteur à haute densité cellulaire avec traitement ultérieur en ligne ultrarapide
WO2003010512A2 (fr) † 2001-07-23 2003-02-06 Accurate Polymers, Inc. Separation solide-liquide a grande vitesse
US20040248260A1 (en) * 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
US20040234499A1 (en) * 2001-10-26 2004-11-25 David Shealy Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
JP2005512522A (ja) * 2001-10-26 2005-05-12 セントカー・インコーポレーテツド Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用
WO2003086451A1 (fr) 2002-04-05 2003-10-23 Centocor, Inc. Proteines derivees de l'immunoglobuline anti il-13 associees a l'asthme, compositions, procedes et utilisations associes
JP2005530845A (ja) * 2002-06-21 2005-10-13 アイデック ファーマシューティカルズ コーポレイション 抗体を濃縮するための緩衝化処方物およびその使用方法
WO2004076485A1 (fr) † 2003-02-28 2004-09-10 Lonza Biologics Plc. Purification d'anticorps par chromatographie d'affinite sur proteine a et chromatographie par echange d'ions
JPWO2004087761A1 (ja) † 2003-03-31 2006-07-27 麒麟麦酒株式会社 ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
ES2349779T5 (es) * 2003-04-04 2013-11-26 Genentech, Inc. Formulaciones de anticuerpos y de proteínas a concentración elevada
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
LT2805728T (lt) * 2003-12-23 2020-05-25 Genentech, Inc. Nauji anti-il 13 antikūnai ir jų naudojimai
CN1234725C (zh) † 2004-04-07 2006-01-04 陈志南 一种高效快速纯化制备片段抗体的方法
AR049390A1 (es) † 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
US20060039910A1 (en) * 2004-08-20 2006-02-23 Amgen Inc. Methods and compositions for treating allergic inflammation
DE602005025525D1 (de) * 2004-11-17 2011-02-03 Amgen Inc Vollständige humane monoklonale antikörper gegen il-13
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
EP2652038A1 (fr) † 2010-10-14 2013-10-23 Ticona GmbH Polyoxyméthylène plastifié

Also Published As

Publication number Publication date
AU2006296399A8 (en) 2008-07-17
IL189983A0 (en) 2008-08-07
NO344859B1 (no) 2020-06-02
AU2006296399B2 (en) 2011-01-20
IL246674B (en) 2019-09-26
HK1210724A1 (en) 2016-05-06
LTPA2021528I1 (fr) 2021-12-27
PL1942939T5 (pl) 2021-10-11
JP2014040461A (ja) 2014-03-06
KR101363777B1 (ko) 2014-02-14
CA2623429A1 (fr) 2007-04-05
IL246674A0 (en) 2016-08-31
JP5820450B2 (ja) 2015-11-24
US20080248048A1 (en) 2008-10-09
IL189983A (en) 2016-11-30
FIC20210042I1 (fi) 2021-11-23
GB0619204D0 (en) 2006-11-08
JP2009510046A (ja) 2009-03-12
EP1942939B2 (fr) 2021-07-07
GB2430883B (en) 2008-03-19
EP1942939B1 (fr) 2018-05-30
GB2430883A (en) 2007-04-11
KR20080054429A (ko) 2008-06-17
NO20081946L (no) 2008-06-27
SI1942939T1 (sl) 2018-10-30
BRPI0616359B8 (pt) 2022-08-30
NO2021050I1 (no) 2021-11-12
BRPI0616359A2 (pt) 2011-06-14
AU2006296399A1 (en) 2007-04-05
SI1942939T2 (sl) 2021-11-30
US9107945B2 (en) 2015-08-18
HUS2100053I1 (hu) 2021-12-28
EP1942939A2 (fr) 2008-07-16
IL230005A (en) 2016-05-31
US20110086038A1 (en) 2011-04-14
BRPI0616359B1 (pt) 2021-09-08
US20160002327A1 (en) 2016-01-07
NL301143I1 (fr) 2021-11-10
FR21C1055I1 (fr) 2021-12-24
NL301143I2 (nl) 2022-02-10
WO2007036745A3 (fr) 2007-08-02
CY1120874T1 (el) 2019-12-11
CA2623429C (fr) 2015-01-13
IL230005A0 (en) 2014-01-30
PL1942939T3 (pl) 2018-10-31
US10358488B2 (en) 2019-07-23
WO2007036745A2 (fr) 2007-04-05

Similar Documents

Publication Publication Date Title
FR21C1055I2 (fr) Composition comprenant un anticorps anti-interleukine 13
FR23C1029I1 (fr) Compositions d'anticorps anti-ctla-4
CY2019041I1 (el) Τροποποιημενα αντισωματα εναντι il-23
CY2018013I1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
FR15C0048I2 (fr) Anticorps antagonistes de il-17
MA29014B1 (fr) Formulations d'anticorps
FR14C0069I2 (fr) Composition pharmaceutique comprenant le lurasidone
NO20053161D0 (no) Mikrobedrepende sammensetning.
DK1771482T3 (da) HER2-antistofsammensætning
NO20076607L (no) TWEAK - bindende antistoff
DK1964852T3 (da) Anti-ilt7-antistof
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
NO20071430L (no) Anti-OX4OL antistoffer
ATE506362T1 (de) 1-aza-bicycloä3.3.1ünonane
DE602006006369D1 (de) Entwicklerzusammensetzungen
DE602005008726D1 (de) Verwendet
DK1568274T3 (da) Stangsystemanordning
DE502005007322D1 (de) Einpresskontakt
DE602005027222D1 (de) Schaumbare zusammensetzung
FR2902649B1 (fr) Ensemble comprenant une composition acide et une composition a base d'hydroxyalkyluree
DE602005017191D1 (de) Geruchsreduzierte waschstück-zusammensetzung
DE602005012986D1 (de) Herbizidzusammensetzung
DE602005019013D1 (de) Tonerzusammensetzung
ATE498308T1 (de) Glyphosate-zusammensetzung
FR2891145B1 (fr) Kit comprenant deux compositions cosmetiques